Ascendis Pharma and Royalty Pharma Announce $150 Million Collaboration
In a significant move within the biopharmaceutical industry, Ascendis Pharma A/S (NASDAQ: ASND) and Royalty Pharma plc have forged a groundbreaking agreement valued at $150 million. This partnership highlights Ascendis Pharma Bone Diseases A/S, a specialized division of Ascendis Pharma, and aims to provide crucial financial support for their innovative treatment, YORVIPATH.
Importance of the Royalty Funding Agreement
This capped synthetic royalty funding agreement, worth $150 million, is particularly important as it depends on the U.S. net sales of YORVIPATH. This treatment is notable for being the first FDA-approved therapy for hypoparathyroidism in adults. Jan Mikkelsen, President and CEO of Ascendis Pharma, expressed excitement about this collaboration, recognizing Royalty Pharma's vital role in financing innovation across the biopharma sector.
YORVIPATH: A Groundbreaking Treatment
YORVIPATH marks a significant leap forward in the management of hypoparathyroidism, a condition marked by insufficient levels of parathyroid hormone that disrupt calcium balance in the body. The launch of YORVIPATH aims to meet the specific medical needs of adults affected by this condition, representing an important advancement in patient care.
Insights from Leadership
Pablo Legorreta, founder and CEO of Royalty Pharma, highlighted the importance of this partnership, underscoring their dedication to promoting innovation that greatly improves patient outcomes. By providing essential funding for the market introduction of YORVIPATH, Royalty Pharma reaffirms its commitment to collaboration and demonstrates its ability to create beneficial funding solutions.
Financial Details of the Agreement
According to the terms of the agreement, Ascendis Pharma will receive an upfront payment of $150 million. In exchange, they will pay a 3% royalty based on the U.S. net sales of YORVIPATH until they achieve a total return of 2.0 times the initial investment. If sales exceed expectations and Royalty Pharma is compensated accordingly by December 31, 2029, the royalty rate may be adjusted to 1.65 times.
Advisory Support for the Deal
The financial advisory for this transaction was provided by Evercore, while legal counsel for Ascendis Pharma was offered by Latham & Watkins and Mazanti-Andersen. Royalty Pharma received legal guidance from Goodwin Procter and Fenwick & West.
About the Companies Involved
Ascendis Pharma is at the forefront of biopharmaceutical innovation, utilizing its proprietary TransCon technology platform to improve patient lives. They are committed to developing potentially best-in-class therapies, driven by their passion for science and dedication to patient care.
Royalty Pharma's Contribution to Healthcare Innovation
Founded in 1996, Royalty Pharma is a prominent buyer of biopharmaceutical royalties, fostering innovation through funding arrangements with entities ranging from academic institutions to large pharmaceutical companies. Their extensive portfolio includes royalties on over 35 commercial products, highlighting their significant role in enhancing access to vital treatments.
Frequently Asked Questions
What does the funding agreement entail?
The agreement provides Ascendis Pharma with $150 million in exchange for a percentage of net sales from YORVIPATH, which targets hypoparathyroidism treatment.
How will this affect YORVIPATH's market presence?
The funding strengthens the launch and market capabilities of YORVIPATH, allowing Ascendis Pharma to effectively deliver this essential treatment.
What technologies does Ascendis Pharma use?
Ascendis Pharma utilizes its innovative TransCon technology to develop therapies aimed at addressing significant medical needs.
Where is Ascendis Pharma based?
Ascendis Pharma is headquartered in Copenhagen, Denmark, with additional offices in Europe and the United States to support its global operations.
Can you explain Royalty Pharma's role?
Royalty Pharma finances innovations in the biopharmaceutical sector by acquiring royalties and co-funding late-stage clinical trials, making substantial contributions to the industry's growth.
